Concepts (256)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| HIV Infections | 25 | 2021 | 11620 | 1.89 | Why? |
| Integrins | 5 | 2019 | 158 | 1.85 | Why? |
| Acquired Immunodeficiency Syndrome | 6 | 2021 | 533 | 1.78 | Why? |
| AIDS Vaccines | 5 | 2019 | 452 | 1.62 | Why? |
| HIV | 8 | 2021 | 1116 | 1.62 | Why? |
| Communicable Diseases, Emerging | 5 | 2020 | 2523 | 1.30 | Why? |
| Antiretroviral Therapy, Highly Active | 4 | 2019 | 952 | 1.18 | Why? |
| Influenza Vaccines | 5 | 2019 | 2941 | 1.14 | Why? |
| National Institute of Allergy and Infectious Diseases (U.S.) | 3 | 2018 | 39 | 1.14 | Why? |
| Biomedical Research | 7 | 2021 | 5270 | 1.04 | Why? |
| Aedes | 2 | 2017 | 380 | 0.97 | Why? |
| Influenza, Human | 7 | 2021 | 10779 | 0.95 | Why? |
| Influenza A virus | 4 | 2021 | 2234 | 0.78 | Why? |
| HIV Envelope Protein gp120 | 2 | 2018 | 267 | 0.75 | Why? |
| Interdisciplinary Research | 1 | 2021 | 266 | 0.74 | Why? |
| Protein Sorting Signals | 1 | 2018 | 104 | 0.71 | Why? |
| Eggs | 1 | 2017 | 43 | 0.71 | Why? |
| Tick-Borne Diseases | 1 | 2018 | 68 | 0.69 | Why? |
| Arboviruses | 1 | 2018 | 76 | 0.68 | Why? |
| Antibody-Producing Cells | 1 | 2017 | 66 | 0.66 | Why? |
| Lyme Disease | 1 | 2018 | 102 | 0.66 | Why? |
| Epidemics | 6 | 2019 | 6407 | 0.66 | Why? |
| History, 21st Century | 6 | 2021 | 1849 | 0.65 | Why? |
| Arbovirus Infections | 1 | 2018 | 104 | 0.64 | Why? |
| Measles Vaccine | 1 | 2019 | 301 | 0.61 | Why? |
| Chikungunya Fever | 2 | 2017 | 345 | 0.58 | Why? |
| History, 20th Century | 5 | 2021 | 1282 | 0.58 | Why? |
| West Nile Fever | 1 | 2017 | 166 | 0.56 | Why? |
| Mosquito Vectors | 1 | 2017 | 351 | 0.56 | Why? |
| Yellow Fever | 1 | 2017 | 231 | 0.53 | Why? |
| Alphavirus Infections | 1 | 2014 | 68 | 0.52 | Why? |
| Gastrointestinal Agents | 1 | 2018 | 393 | 0.52 | Why? |
| Zika Virus Infection | 2 | 2017 | 1920 | 0.51 | Why? |
| Recombinant Fusion Proteins | 1 | 2018 | 919 | 0.49 | Why? |
| Sexually Transmitted Diseases | 1 | 2020 | 694 | 0.48 | Why? |
| Insect Vectors | 1 | 2014 | 227 | 0.47 | Why? |
| Tuberculosis | 2 | 2018 | 2895 | 0.46 | Why? |
| Measles | 1 | 2019 | 608 | 0.44 | Why? |
| Antibodies, Monoclonal | 4 | 2019 | 8041 | 0.44 | Why? |
| Vaccines, Synthetic | 3 | 2021 | 3231 | 0.44 | Why? |
| Viral Vaccines | 7 | 2021 | 7560 | 0.43 | Why? |
| Simian Acquired Immunodeficiency Syndrome | 3 | 2018 | 154 | 0.42 | Why? |
| Health Planning | 1 | 2017 | 607 | 0.41 | Why? |
| Orthomyxoviridae | 1 | 2019 | 1168 | 0.41 | Why? |
| Viremia | 4 | 2019 | 1020 | 0.39 | Why? |
| Disease Outbreaks | 5 | 2019 | 27595 | 0.39 | Why? |
| Pandemics | 18 | 2021 | 389249 | 0.39 | Why? |
| Communicable Disease Control | 6 | 2021 | 29620 | 0.38 | Why? |
| United States | 15 | 2021 | 46150 | 0.37 | Why? |
| HIV-1 | 8 | 2018 | 3365 | 0.37 | Why? |
| Virus Diseases | 2 | 2018 | 3779 | 0.37 | Why? |
| CD4 Lymphocyte Count | 3 | 2019 | 1517 | 0.36 | Why? |
| International Cooperation | 3 | 2020 | 3436 | 0.36 | Why? |
| Immunologic Memory | 3 | 2018 | 3362 | 0.34 | Why? |
| Tuberculosis Vaccines | 2 | 2018 | 89 | 0.34 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2019 | 9335 | 0.33 | Why? |
| Humans | 59 | 2021 | 930598 | 0.32 | Why? |
| Hemorrhagic Fever, Ebola | 1 | 2018 | 1475 | 0.32 | Why? |
| CD4-Positive T-Lymphocytes | 8 | 2019 | 4545 | 0.31 | Why? |
| Anti-HIV Agents | 4 | 2020 | 2209 | 0.31 | Why? |
| Research | 1 | 2018 | 2115 | 0.28 | Why? |
| Zika Virus | 1 | 2017 | 1924 | 0.28 | Why? |
| Americas | 2 | 2017 | 418 | 0.27 | Why? |
| Simian Immunodeficiency Virus | 3 | 2018 | 251 | 0.27 | Why? |
| Leukapheresis | 1 | 2003 | 20 | 0.27 | Why? |
| Immunotherapy | 1 | 2018 | 2421 | 0.27 | Why? |
| Zoonoses | 1 | 2018 | 3034 | 0.27 | Why? |
| History, 19th Century | 2 | 2017 | 384 | 0.26 | Why? |
| National Institutes of Health (U.S.) | 3 | 2021 | 443 | 0.26 | Why? |
| Global Health | 4 | 2020 | 13911 | 0.26 | Why? |
| Public Health | 5 | 2021 | 16359 | 0.24 | Why? |
| Viral Load | 4 | 2019 | 15850 | 0.23 | Why? |
| B-Lymphocytes | 1 | 2017 | 4418 | 0.23 | Why? |
| B-Lymphocyte Subsets | 1 | 2003 | 372 | 0.22 | Why? |
| Animals | 14 | 2020 | 78931 | 0.22 | Why? |
| Adaptive Clinical Trials as Topic | 1 | 2020 | 54 | 0.22 | Why? |
| Disease Models, Animal | 3 | 2020 | 10998 | 0.22 | Why? |
| Cell Communication | 1 | 2003 | 396 | 0.22 | Why? |
| Myocardial Infarction | 1 | 2017 | 3361 | 0.21 | Why? |
| United States Health Resources and Services Administration | 1 | 2019 | 4 | 0.20 | Why? |
| Genetic Drift | 1 | 2019 | 54 | 0.20 | Why? |
| Lyme Disease Vaccines | 1 | 2018 | 3 | 0.19 | Why? |
| Stress, Physiological | 1 | 2003 | 378 | 0.19 | Why? |
| HIV Seronegativity | 1 | 2019 | 112 | 0.19 | Why? |
| Urban Health | 1 | 2002 | 382 | 0.19 | Why? |
| Immunity, Heterologous | 1 | 2019 | 129 | 0.18 | Why? |
| Ixodes | 1 | 2018 | 58 | 0.18 | Why? |
| Pneumonia, Viral | 7 | 2021 | 243684 | 0.18 | Why? |
| Anti-Vaccination Movement | 1 | 2019 | 74 | 0.18 | Why? |
| Antigenic Variation | 1 | 2019 | 249 | 0.18 | Why? |
| Masks | 1 | 2020 | 8528 | 0.17 | Why? |
| Ticks | 1 | 2018 | 107 | 0.17 | Why? |
| Cuba | 1 | 2018 | 202 | 0.17 | Why? |
| Sustained Virologic Response | 1 | 2019 | 378 | 0.16 | Why? |
| Public-Private Sector Partnerships | 1 | 2020 | 259 | 0.16 | Why? |
| HIV Antigens | 1 | 2017 | 102 | 0.16 | Why? |
| Disease Vectors | 1 | 2018 | 208 | 0.16 | Why? |
| Point Mutation | 1 | 2019 | 481 | 0.15 | Why? |
| Poverty | 1 | 2007 | 2302 | 0.15 | Why? |
| Remission Induction | 1 | 2019 | 950 | 0.15 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.15 | Why? |
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2019 | 511 | 0.14 | Why? |
| Plasmids | 1 | 2018 | 840 | 0.14 | Why? |
| History, 16th Century | 1 | 2014 | 104 | 0.14 | Why? |
| Crowding | 1 | 2020 | 731 | 0.14 | Why? |
| Research Support as Topic | 1 | 2018 | 327 | 0.14 | Why? |
| California | 1 | 2021 | 2047 | 0.13 | Why? |
| Environment | 1 | 2020 | 769 | 0.13 | Why? |
| Common Cold | 1 | 2020 | 645 | 0.13 | Why? |
| History, 18th Century | 1 | 2014 | 192 | 0.13 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.13 | Why? |
| Coronavirus | 2 | 2020 | 18339 | 0.13 | Why? |
| Health Education | 2 | 2021 | 1539 | 0.13 | Why? |
| Glycosylation | 1 | 2018 | 1255 | 0.13 | Why? |
| Antiviral Agents | 3 | 2021 | 41703 | 0.13 | Why? |
| Lymphocyte Activation | 1 | 2003 | 2742 | 0.13 | Why? |
| Demography | 1 | 2020 | 1660 | 0.13 | Why? |
| United States Food and Drug Administration | 1 | 2021 | 1276 | 0.13 | Why? |
| Withholding Treatment | 1 | 2019 | 798 | 0.13 | Why? |
| Ventilation | 1 | 2020 | 1145 | 0.13 | Why? |
| Clinical Trials as Topic | 3 | 2021 | 7330 | 0.12 | Why? |
| Influenza B virus | 1 | 2019 | 815 | 0.12 | Why? |
| Virus Replication | 5 | 2021 | 14331 | 0.12 | Why? |
| Disease Transmission, Infectious | 3 | 2021 | 9044 | 0.11 | Why? |
| Ferrets | 1 | 2017 | 1201 | 0.11 | Why? |
| Cardiovascular Diseases | 1 | 2017 | 11497 | 0.11 | Why? |
| Antigens, Viral | 2 | 2019 | 6298 | 0.11 | Why? |
| Interleukin-7 | 1 | 2012 | 148 | 0.11 | Why? |
| Chikungunya virus | 1 | 2014 | 339 | 0.11 | Why? |
| Ebolavirus | 1 | 2018 | 834 | 0.11 | Why? |
| Lymphocytes | 1 | 2003 | 3056 | 0.11 | Why? |
| Hand Hygiene | 1 | 2020 | 1493 | 0.10 | Why? |
| Disease Reservoirs | 1 | 2019 | 1672 | 0.10 | Why? |
| Disease Progression | 2 | 2020 | 13580 | 0.10 | Why? |
| Vaccines | 2 | 2020 | 3692 | 0.10 | Why? |
| Epitopes | 2 | 2019 | 4113 | 0.10 | Why? |
| DNA, Viral | 2 | 2018 | 2521 | 0.10 | Why? |
| Dendritic Cells | 1 | 2018 | 1330 | 0.09 | Why? |
| Dexamethasone | 1 | 2020 | 2055 | 0.09 | Why? |
| Africa | 1 | 2018 | 2986 | 0.09 | Why? |
| Anti-Infective Agents | 1 | 2020 | 1766 | 0.09 | Why? |
| Mass Vaccination | 1 | 2019 | 1101 | 0.09 | Why? |
| Immunogenicity, Vaccine | 2 | 2021 | 4624 | 0.09 | Why? |
| Basic Reproduction Number | 1 | 2020 | 2676 | 0.09 | Why? |
| Antibodies, Neutralizing | 4 | 2019 | 25288 | 0.09 | Why? |
| Immunization Programs | 1 | 2021 | 2006 | 0.09 | Why? |
| Immunization | 1 | 2017 | 2019 | 0.08 | Why? |
| Asymptomatic Diseases | 1 | 2020 | 3444 | 0.08 | Why? |
| Drug Discovery | 1 | 2020 | 3092 | 0.08 | Why? |
| Immune Evasion | 1 | 2017 | 2081 | 0.08 | Why? |
| Sex Factors | 2 | 2020 | 11014 | 0.08 | Why? |
| Seasons | 1 | 2019 | 4071 | 0.08 | Why? |
| Climate Change | 1 | 2014 | 901 | 0.08 | Why? |
| Patient Safety | 1 | 2021 | 4885 | 0.07 | Why? |
| CD8-Positive T-Lymphocytes | 3 | 2017 | 5837 | 0.07 | Why? |
| Child, Preschool | 2 | 2019 | 36283 | 0.07 | Why? |
| Chronic Disease | 2 | 2017 | 5139 | 0.07 | Why? |
| Aerosols | 1 | 2020 | 5393 | 0.07 | Why? |
| Politics | 1 | 2017 | 1824 | 0.07 | Why? |
| B7-1 Antigen | 1 | 2003 | 39 | 0.07 | Why? |
| Health Services Accessibility | 2 | 2019 | 10697 | 0.07 | Why? |
| B7-2 Antigen | 1 | 2003 | 56 | 0.07 | Why? |
| Cell Division | 1 | 2003 | 136 | 0.06 | Why? |
| CD40 Antigens | 1 | 2003 | 118 | 0.06 | Why? |
| Gastrointestinal Diseases | 1 | 2018 | 2580 | 0.06 | Why? |
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 343 | 0.06 | Why? |
| Life Expectancy | 1 | 2007 | 474 | 0.06 | Why? |
| Immunity, Humoral | 1 | 2017 | 4849 | 0.06 | Why? |
| Macaca mulatta | 3 | 2018 | 3716 | 0.06 | Why? |
| HIV Antibodies | 2 | 2018 | 776 | 0.06 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2020 | 10649 | 0.06 | Why? |
| Heat-Shock Proteins | 1 | 2003 | 226 | 0.05 | Why? |
| Receptors, Antigen, B-Cell | 1 | 2003 | 424 | 0.05 | Why? |
| Protein Interaction Domains and Motifs | 2 | 2018 | 2134 | 0.05 | Why? |
| Immunization, Passive | 1 | 2017 | 10067 | 0.05 | Why? |
| Social Isolation | 1 | 2020 | 5932 | 0.05 | Why? |
| Intestinal Mucosa | 2 | 2018 | 1046 | 0.05 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.05 | Why? |
| Cells, Cultured | 2 | 2018 | 5835 | 0.05 | Why? |
| Female | 8 | 2020 | 380317 | 0.05 | Why? |
| SAIDS Vaccines | 1 | 2018 | 25 | 0.05 | Why? |
| Mutation | 2 | 2017 | 12376 | 0.05 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.05 | Why? |
| Immune Tolerance | 1 | 2003 | 608 | 0.04 | Why? |
| Genetic Variation | 1 | 2012 | 3919 | 0.04 | Why? |
| Mice | 1 | 2018 | 21357 | 0.04 | Why? |
| Tretinoin | 1 | 2018 | 99 | 0.04 | Why? |
| Antigens, CD | 1 | 2003 | 984 | 0.04 | Why? |
| Lymphoid Tissue | 1 | 2018 | 162 | 0.04 | Why? |
| Coinfection | 1 | 2018 | 6820 | 0.04 | Why? |
| Down-Regulation | 1 | 2003 | 1416 | 0.04 | Why? |
| Macaca | 1 | 2018 | 388 | 0.04 | Why? |
| Receptors, CCR5 | 1 | 2018 | 186 | 0.04 | Why? |
| Pregnancy | 1 | 2019 | 23879 | 0.04 | Why? |
| Half-Life | 1 | 2017 | 298 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Male | 6 | 2020 | 367725 | 0.04 | Why? |
| Treatment Outcome | 2 | 2021 | 51732 | 0.03 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.03 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.03 | Why? |
| env Gene Products, Human Immunodeficiency Virus | 1 | 2018 | 386 | 0.03 | Why? |
| Risk Factors | 2 | 2020 | 71621 | 0.03 | Why? |
| Membrane Glycoproteins | 1 | 2003 | 2273 | 0.03 | Why? |
| Adult | 4 | 2019 | 244371 | 0.03 | Why? |
| Vaccines, DNA | 1 | 2020 | 871 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.03 | Why? |
| Peptide Hydrolases | 1 | 2021 | 1269 | 0.03 | Why? |
| China | 1 | 2020 | 50654 | 0.03 | Why? |
| Public Health Practice | 1 | 2021 | 945 | 0.03 | Why? |
| Middle Aged | 3 | 2020 | 270681 | 0.03 | Why? |
| Gene Expression Profiling | 1 | 2003 | 3788 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.03 | Why? |
| Developing Countries | 1 | 2007 | 4283 | 0.03 | Why? |
| CD4-CD8 Ratio | 1 | 2012 | 235 | 0.03 | Why? |
| Cell Proliferation | 1 | 2018 | 1973 | 0.03 | Why? |
| Adjuvants, Immunologic | 1 | 2020 | 1709 | 0.03 | Why? |
| Up-Regulation | 1 | 2018 | 2249 | 0.03 | Why? |
| Blood Donors | 1 | 2003 | 2956 | 0.03 | Why? |
| Child | 1 | 2019 | 70012 | 0.02 | Why? |
| Cell Line, Tumor | 1 | 2018 | 3608 | 0.02 | Why? |
| Carrier State | 1 | 2021 | 2100 | 0.02 | Why? |
| Uganda | 1 | 2012 | 1057 | 0.02 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.02 | Why? |
| Selection, Genetic | 1 | 2012 | 691 | 0.02 | Why? |
| Thymus Gland | 1 | 2009 | 126 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2017 | 3395 | 0.02 | Why? |
| In Situ Hybridization | 1 | 2009 | 390 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2003 | 9893 | 0.02 | Why? |
| Attitude to Health | 1 | 2021 | 2002 | 0.02 | Why? |
| Endothelial Cells | 1 | 2018 | 2048 | 0.02 | Why? |
| African Americans | 1 | 2002 | 3363 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2018 | 5440 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2019 | 51949 | 0.02 | Why? |
| RNA, Messenger | 1 | 2020 | 5131 | 0.02 | Why? |
| Binding Sites | 1 | 2018 | 6201 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2018 | 6543 | 0.02 | Why? |
| Protease Inhibitors | 1 | 2021 | 3630 | 0.02 | Why? |
| RNA, Viral | 3 | 2012 | 32276 | 0.02 | Why? |
| Cluster Analysis | 1 | 2012 | 3001 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2012 | 2830 | 0.02 | Why? |
| Logistic Models | 1 | 2018 | 9089 | 0.02 | Why? |
| T-Lymphocytes | 1 | 2020 | 6670 | 0.02 | Why? |
| Lymph Nodes | 1 | 2009 | 1060 | 0.01 | Why? |
| Lymphocyte Subsets | 1 | 2009 | 987 | 0.01 | Why? |
| Protein Binding | 1 | 2018 | 11430 | 0.01 | Why? |
| Signal Transduction | 1 | 2018 | 7207 | 0.01 | Why? |
| Drug Evaluation, Preclinical | 1 | 2012 | 3347 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2021 | 22971 | 0.01 | Why? |
| Acute Disease | 1 | 2012 | 6029 | 0.01 | Why? |
| Prognosis | 1 | 2002 | 32490 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 2012 | 6740 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2003 | 53120 | 0.01 | Why? |
| Young Adult | 2 | 2018 | 93724 | 0.01 | Why? |
| Phylogeny | 1 | 2012 | 13341 | 0.01 | Why? |
| Vaccination | 1 | 2018 | 19050 | 0.01 | Why? |
| Adolescent | 1 | 2012 | 86841 | 0.00 | Why? |
Fauci's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(256)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(74)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_